参会/布展/演讲，早鸟报名中2025 年 8 月 1 日医麦客新闻 eMedClub News全球核药市场，特别是放射性核素偶联药物（RDC)领域，正迎来爆发式增长。近日，远大医药 SIR-Spheres®钇 [90Y] 微球注射液（易甘泰®）提前斩获 FDA 肝细胞癌新适应症批准，成为全球首个且唯一拥有肝癌双适应症的选择性内放射治疗产品。同月，国内核药再现大笔融资。7 月 19 日，东诚药业公告...
Source Link参会/布展/演讲，早鸟报名中2025 年 8 月 1 日医麦客新闻 eMedClub News全球核药市场，特别是放射性核素偶联药物（RDC)领域，正迎来爆发式增长。近日，远大医药 SIR-Spheres®钇 [90Y] 微球注射液（易甘泰®）提前斩获 FDA 肝细胞癌新适应症批准，成为全球首个且唯一拥有肝癌双适应症的选择性内放射治疗产品。同月，国内核药再现大笔融资。7 月 19 日，东诚药业公告...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.